File: '\\swfile\EmailIn\20260319 153303 Attachment Asep NR O'Shaughnessy appointed to BoD_031926_.FINALdocx.docx'

Asep Medical Holdings Inc.

FOR IMMEDIATE RELEASE

Asep Medical Holdings Inc. welcomes

Mr. Thomas O'Shaughnessy to the Board of Directors

Vancouver, BC - March 18, 2026 - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP | OTCQB: SEPSF) today announced the appointment of Mr. Thomas O'Shaughnessy to its Board of Directors. The appointment takes effect immediately.

Mr. O'Shaughnessy is the CEO of Onco-Innovations Limited, a Canadian-based biotechnology company dedicated to cancer research and treatment, specializing in oncology. He is also the Founder and Managing Principal of Carnarvon Health Industry Solutions Inc., a health and life sciences consultancy firm. Throughout his extensive career, he has worked with some of the largest health organizations and systems in Canada and globally on assignments from business and technology strategy development and execution to strategic management, digital health implementation, and senior stakeholder engagement. A trusted advisor for high-stakes transformation initiatives and mission-critical implementation programs, he leads high-performance organizations and teams on a national scale.

"I am honoured to take on this role with the Asep team and look forward to building momentum for both the sepsis diagnostic technology and the anti-biofilm peptide. As a former Asep advisory board member, I understand the Company's incredible potential, and I am eager to contribute to its future success," said Mr. O'Shaughnessy.

"We are very pleased to welcome Mr. O'Shaughnessy to the Asep Board of Directors," commented Dr. Richard Heinzl, Asep's Interim CEO and fellow Board member. "His depth of industry and leadership experience will make an immediate impact on the Company, and we look forward to reaping the rewards of his strategic and operational expertise," Dr. Heinzl added.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a controlling interest in two private subsidiary companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include, but are not limited to, the successful execution of the Company's business plan, the development, testing, and commercialization of its sepsis diagnostic test (Sepset), and other statements regarding the Company's proposed business plans and technologies. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as

required by applicable law.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin

Asep Medical Holdings Inc.

E. chris@asepmedical.com

T. 604-362-3654